JAK2/mTOR抑制虽减少Th1/Th17细胞仍未能预防急性GVHD:2期试验最终结果
这项单臂2期试验纳入28例8/8 HLA相合同胞供者异基因造血干细胞移植患者,评估帕克替尼联合西罗莫司和他克莫司预防GVHD。方案达到主要终点(第+21天pSTAT3+CD4+T细胞降至9.62%),Th1/Th17细胞减少,但第+100天II-IV级急性GVHD累积发生率为46%,与历史SIR/TAC的43%相似,未能改善急性GVHD预防。
要点
- 帕克替尼+西罗莫司+他克莫司达到主要终点,第+21天pSTAT3+CD4+T细胞为9.62%。
- 第+21天Th1/Th17细胞减少,调节性T细胞与Th1/Th17比值升高。
- 第+100天II-IV级急性GVHD累积发生率46%,与历史SIR/TAC的43%相似。
核心结论
- 帕克替尼联合西罗莫司和他克莫司虽抑制pSTAT3并减少Th1/Th17细胞,但未能改善急性GVHD预防。
研究设计与样本
- 单臂2期试验(NCT02891603),纳入28例接受8/8 HLA相合异基因造血干细胞移植的血液系统恶性肿瘤或骨髓增殖性肿瘤患者。
- 允许减低强度或清髓性预处理;帕克替尼推荐2期剂量为第0天至+70天口服100 mg每日两次,联合西罗莫司和他克莫司。
主要发现
- 主要终点达到:第+21天pSTAT3+CD4+T细胞百分比降至9.62%(主要终点为≤35%)。
- 第+21天Th1/Th17细胞减少,帕克替尼推荐2期剂量组较剂量水平1组调节性T细胞与Th1和Th17细胞比值升高。
- 第+100天II-IV级急性GVHD累积发生率为46%,历史SIR/TAC值为43%。
关键数值与推荐
- 主要终点:第+21天pSTAT3+CD4+T细胞百分比≤35%,实际降至9.62%。
- 帕克替尼推荐2期剂量:第0天至+70天口服100 mg每日两次。
- 第+100天II-IV级急性GVHD累积发生率:帕克替尼+西罗莫司+他克莫司组46% vs 历史SIR/TAC组43%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our phase 1 graft-versus-host disease (GVHD) prevention trial of JAK2 inhibitor, pacritinib (PAC; recommended phase 2 dose: 100 mg orally twice a day on day 0 to +70) plus sirolimus and tacrolimus (SIR/TAC) demonstrated the regimen was safe and free of pan-JAK myelosuppression after allogeneic hematopoietic cell transplantation (alloHCT). PAC inhibits interleukin 6 (IL-6) receptor activity and pathogenic T helper cell 1 (Th1)/Th17 differentiation in preclinical models and the phase 1 trial. Herein, we report on our completed phase 2 trial of PAC/SIR/TAC after 8/8 human leukocyte antigen matched alloHCT. This single-arm phase 2 trial (NCT02891603) was powered to determine if PAC/SIR/TAC suppressed percentage phosphorylated STAT3 (pSTAT3)+ CD4+ T cells at day +21 (primary end point: percentage pSTAT3+ CD4+ T cells ≤ 35%) and estimated grade II to IV acute GVHD by day +100. The impact of PAC/SIR/TAC on T-cell subsets, CD28 (pS6 and pH3ser10), and IL-2 receptor (pSTAT5) signal transduction was also evaluated. Eligible patients (n = 28) received alloHCT for hematologic malignancies or myeloproliferative neoplasms. Reduced or myeloablative intensity conditioning was permitted. PAC/SIR/TAC met the primary end point, reducing percentage pSTAT3+ CD4+ T cells to 9.62% at day +21. Th1/Th17 cells were decreased at day +21, increasing the ratio of regulatory T cells to Th1 and Th17 cells with PAC/SIR/TAC at recommended phase 2 dose PAC compared with dose level 1 PAC. The cumulative incidence of grade II to IV acute GVHD by day +100 with PAC/SIR/TAC was similar to historic SIR/TAC values (46% vs 43%). Although PAC/SIR/TAC suppressed pSTAT3 and Th1/Th17 cells, the regimen did not improve acute GVHD prevention.
引用
- Pidala J, Holtan SG, Walton K, et al. JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results. Blood. 2024. PMID: 39046783. doi:10.1182/blood.2024024789
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。